GALT vs MDGL
GALT: Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer. MDGL: Madrigal is a commercial-stage biotech company exclusively focused on Rezdiffra, the first FDA-approved treatment for MASH with moderate-to-advanced fibrosis, now scaling US and EU commercialization.
Side-by-side fundamentals
| Metric | GALT | MDGL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.50 | $537.65 | |
| Market cap as of 2026-07-23 | $253M | $12.4B | |
| Net margin as of 2026-07-23 | n/a | -27.3% | |
| Gross margin as of 2026-07-23 | n/a | +93.1% | |
| Operating margin as of 2026-07-23 | n/a | -27.9% | |
| ROE as of 2026-07-23 | -258.6% | -50.1% | MDGL higher |
| ROA as of 2026-07-23 | -164.7% | -25.4% | MDGL higher |
| Debt / equity as of 2026-07-23 | 11.09 | 0.63 | MDGL lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +256.8% | |
| Beta as of 2026-07-23 | 0.36 | -1.06 | |
| 1-year return as of 2026-07-22 close | +22.4% | +71.6% | MDGL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.